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Background: Pleomorphic xanthoastrocytoma (PXA) is a rare WHO grade II tumor accounting for less than 1% of
all astrocytomas. Malignant transformation into PXA with anaplastic features, is unusual and correlates with poorer
outcome of the patients.
Methods: Using a DNA methylation custom array, we have quantified the DNA methylation level on the promoter
sequence of 807 cancer-related genes of WHO grade II (n = 11) and III PXA (n = 2) and compared to normal brain
tissue (n = 10) and glioblastoma (n = 87) samples. DNA methylation levels were further confirmed on independent
samples by pyrosequencing of the promoter sequences.
Results: Increasing DNA promoter hypermethylation events were observed in anaplastic PXA as compared with
grade II samples. We further validated differential hypermethylation of CD81, HCK, HOXA5, ASCL2 and TES on
anaplastic PXA and grade II tumors. Moreover, these epigenetic alterations overlap those described in glioblastoma
patients, suggesting common mechanisms of tumorigenesis.
Conclusions: Even taking into consideration the small size of our patient populations, our data strongly suggest
that epigenome-wide profiling of PXA is a valuable tool to identify methylated genes, which may play a role in the
malignant progression of PXA. These methylation alterations may provide useful biomarkers for decision-making in
those patients with low-grade PXA displaying a high risk of malignant transformation.
Keywords: Epigenetics, DNA methylation, Glioblastoma, Pleomorphic xanthoastrocymaBackground
Pleomorphic xanthoastrocytoma (PXA) is a rare WHO
grade II tumor accounting for less than 1% of all astro-
cytomas. They are usually hemispheric, and often they
affect children and young adults (median age 26 years)
with a frequent history of chronic epilepsy at presenta-
tion [1-3]. The majority of the tumors occur in the
supratentorial compartment, mostly in the temporal lobe
[1,4]; rarely, they were observed in thalamus, cerebellum,
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unless otherwise stated.Histologically, PXA shows a pleomorphic appearance,
an intense reticulin network and lipid deposits within
ovoid and spindled tumor cells. Giant tumor cells, eo-
sinophilic granular bodies and lymphocytic infiltrates are
also observed. Immunopositivity for glial fibrillary acidic
protein (GFAP) is virtually always encountered. The
mitotic activity is absent or very low and MIB-1 labeling
index is frequently <1%.
The biological behavior is usually benign with a 10-
years survival rate of 70% and a recurrence-free lapse of
61% [8]. Nevertheless, gradeII PXA may undergo malig-
nant transformation in up to 15-20% [8]. Thus, PXA
with elevated mitotic activity (≥ 5 mitoses per 10 high-
power fields) and/ or presence of necrosis has been clas-
sified as “PXA with anaplastic features” [1,8]. In these
cases, the rate of recurrence has been observed to be
much higher and the survival time clearly shorter [8].
These malignant forms are largely responsible for thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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particularly relevant considering that PXA is often en-
countered in children and young adults.
Epigenetic alterations are able to modulate gene activ-
ity without affecting their nucleotide sequence. Aberrant
methylation has been recognized as a hallmark of hu-
man cancer, and DNA methylation patterns are altered
in all types of cancers analyzed, affecting virtually all
cellular pathways trough methylation-mediated silencing
of regulator genes such as VHL, p16INK4a, E-cadherin,
hMLH1, BRCA1 and LKB1, and many others [9,10]. In
cancer cells a wide-ranging process leading to global
changes in DNA methylation patterns takes place. Specif-
ically, a global hypomethylation process happening mainly
at intergenic regions and repetitive sequences, as well as
local promoter DNA hypermethylation that affects usually
unmethylated CpG-rich DNA sequences mapping to
tumor-suppressor genes. Thus, their activity is abrogated
by means of transcriptional repression [11,12].
Although an increasing interest about aberrant DNA
methylation in gliomas exists, the epigenetic profile of
astrocytic tumors remains only partially devised, which
is especially true for PXA. Widespread hypomethylation
[13] might play a role in the pathogenesis of gliomas
through activation of oncogenes, loss of imprinting, or
the promotion of genomic instability which, in turn ex-
acerbates the tumorigenic phenotype of the cell. More-
over, the importance of aberrant DNA methylation of
CpG island promoter regions in the pathogenesis of gli-
omas, oligodendrogliomas, ependymomas and pituitary
adenomas is highlighted by the observation of hyperme-
thylation of a wide variety of genes associated with tumor
suppression (RB1, VHL, EMP3, RASSF1A, CITED4, BLU),
cell cycle regulation (p16INK4a, p15INK4b), DNA repair
(MGMT, hMLH1), and tumor invasion and apoptosis
(DAPK, TIMP3, CDH1, SOCS3) [13-24]. MGMT is an-
other good example of a DNA repair gene undergoing
methylation-mediated inactivation in human cancer [25],
including GBM [26].
It has recently become evident that the methylation
signature of astrocytic tumors appears to be class-
specific. Analyzing a panel of 7 genes (CDKN2B, PTGS2,
CALCA, MYOD1, THBS1, TIMP3 and CDH1) Uhlman
and colleagues observed differences in the methylation
status in astrocytomas WHO grades II, III and IV [27].
Concerning PXA there is almost no data available from
the literature reporting on epigenetic signatures and only
a specific report focusing on MGMT [28] methylation
status has been published so far.
In the present study we have analyzed the DNA
methylation profiles of PXA WHO grade II (n = 9) and
PXA with anaplastic features (n = 2). Brain tissue ob-
tained by epilepsy neurosurgical procedures in patients
without brain tumors (n = 10) and GBM consecutivesamples (n = 87, previously analyzed [29]) were included
in the DNA methylation analysis. For this purpose, we
have investigated the DNA methylation alterations follow-
ing a microarray-based DNA methylation approach as well
as pyrosequencing of selected genes for further validation.
Methods
Patient samples and controls
The study was approved by the Ethics Committee of the
School of Medicine, University of Göttingen (project
number 11/8/13), and patients provided written informed
consent to participate on the study, as well as for publish-
ing the images and clinical information. All PXA (n = 13
tumors, 12 patients) and GBM patients (n = 87) had
undergone surgery with the goal of maximal possible
tumor resection. One anaplastic PXA (PXA-5) was the
local relapse of a grade II PXA (PXA-4), one year after
complete tumor resection (Table 1). All patient IDs have
been appropriately codified to ensure privacy protection.
Normal human adult brain (NB, n = 10) tissue obtained
from epilepsy neurosurgical procedures, and post-mortem
from healthy individuals was included in the study as nor-
mal control. Tumor samples were frozen in liquid nitro-
gen and stored at –80°C. Tumor tissue was evaluated by
experienced neuropathologists according to the 2007
WHO classification criteria. DNA from tumor specimens
was isolated applying the QIAamp® DNA Mini Kit
(Qiagen, Hilden, Germany). Informed consent for sam-
ples and data analysis was obtained from each patient or
the patient’s carer. The design of this analysis conforms to
standards currently applied in Germany. Survival times
were collected for all cases and were calculated from the
time of diagnosis to death, or last contact in the case of
living patients.
DNA methylation profiling using universal BeadArrays
DNA methylation profiling was performed with the
GoldenGate Methylation Cancer Panel I assay (Illumina
Inc., San Diego CA) on a total of 8 WHO grade II PXA,
2 anaplastic PXA, 87 GBM samples and 10 normal brain
tissue samples as control. The panel was developed to
assay 1,505 CpG sites selected from 807 cancer-related
genes, including oncogenes and tumor suppressor genes,
imprinted genes, genes involved in various signaling
pathways, and those responsible for DNA repair, cell
cycle control, metastasis, cell migration and invasion,
differentiation and apoptosis.
Methylation assay was performed following manufac-
turer’s instructions. Briefly, bisulphite conversion of DNA
samples was carried out using the EZ DNA methylation
kit (Zymo Research, Orange, CA). After bisulphite treat-
ment, the remaining assay steps were performed using
Illumina-supplied reagents and conditions. We excluded
84 CpGs mapping to X chromosome to avoid gender-
Table 1 Histopathological characterization of PXA patients
PXA patients Diagnosis Gender, age ICH features Brain localization
BRAF V600E negative (no mutation)
CD34 positive.
PXA-1 PXA WHO grade II 18y., female GFAP positive. right frontal
MIB-1:1%
IDH1 R132H negative (no mutation).
GFAP positive.
PXA-2 PXA WHO grade II 17y., female MIB-1: 1%. right temporal
No tumor tissue available for BRAF/
CD34 characterization
BRAF V600E positive (mutated)
CD34 focal positive
PXA-3 PXA WHO grade II 34y., female GFAP. Positive. left temporal
MIB-1: <1%.
IDH1 R132H negative (no mutation)
BRAF V600E negative (no mutation)
CD34 positive
Mitotic index <5 mitoses/10 HPF
PXA-4 precursor of PXA-5 PXA WHO grade II 59y., male Immunopositivity for GFAP, S100,
MAP2,
right parietal
vimentin and EMA
MIB-1: 5-10%
IDH1 R132H negative (no mutation)
BRAF V600E negative (no mutation)
CD34 positive
Mitotic index >5mitoses/10 HPF
PXA-5 PXA with anaplastic features 59y., male Immunopositivity for GFAP, S100,
MAP2,
right parietal
vimentin and EMA
MIB-1: 10-15%
IDH1 R132H negative (no mutation)
BRAF V600 E negative (no mutation)
CD34 positive
PXA-6 PXA with anaplastic features 22y., male GFAP positive right temporal
MIB-1: 5%.
IDH1 R132H negative (no mutation)
BRAF V600 E negative (no mutation)
CD34 positive
PXA-7 PXA WHO grade II 44y., female Immunopositivity for GFAP right temporal
MIB-1: 1%.
IDH1 R132H negative (no mutation)
BRAF V600 E negative (no mutation)
CD34 positive
PXA-8 PXA WHO grade II 20y., male Immunopositivity for GFAP. right parieto-occipital
MIB-1: <1%.
IDH1 R132H negative (no mutation)
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Table 1 Histopathological characterization of PXA patients (Continued)
BRAF V600 E negative (no mutation)
CD34 positive
PXA-9 PXA WHO grade II 78y., female Immunopositivity for GFAP. right temporo-parietal
MIB-1: <1%.
IDH1 R132H negative (no mutation)
PXA-10 PXA WHO grade II 15y., female
BRAFV600E negative (no mutation)
right occipital
CD34 positive
Immunopositivity for GFAP.
MIB-1: 1%.
PXA-11 PXA WHO grade II 52y., male
BRAFV600E negative (no mutation)
left occipital
CD34 positive
Immunopositivity for GFAP.
MIB-1: < 1%.
PXA-12 PXA WHO grade II 17 y., male
BRAFV600E positive (mutated)
left parietal
CD34 negative
Immunopositivity for GFAP.
MIB-1: 1%.
PXA-13 PXA WHO grade II 37 y., female
BRAFV600E positive (mutated)
right parietal
CD34 focal positive
Immunopositivity for GFAP
MIB-1: < 1%
Patients undergoing surgical resection of diagnosed pleomorphic xanthoastrocytoma of diverse grade were investigated for specific features characteristic of this
tumor type.
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probabilities (comparing signal intensities against back-
ground noise) for all CpGs and excluded those probes
with values of P > 0.01 in more than 10% of cases. In the
final analysis, 1,390 CpGs mapping to 762 genes were
used in the subsequent statistical analyses.
Data analysis and definition of DNA methylation patterns
For further analyses, only the 1,390 autosomal CpGs that
met our quality criteria were used. In order to distin-
guish groups of patients according to their DNA methy-
lation patterns, we selected only the informative probes,
that is, considering those probes with SD > 0.05 between
patients. We sought to identify genes affected by DNA
hypermethylation in the precursor grade II PXA (PXA-4)
that are further maintained in the anaplastic relapsed
tumor (PXA-5) and in the analyzed glioblastoma samples,
in comparison with the average values of grade II PXA
cases and normal brain. The glioblastoma patients used in
this study for comparison purposes were described in de-
tail elsewhere [29]. To this aim, we set up a threshold in-
crement of 30% in methylation, as has been previously
reported to result in expression differences [30], when
comparing the averaged anaplastic and precursor PXA
samples (PXA-4 and PXA-5), the averaged grade II PXA
cases (PXA1-3) and the GBM patients. Candidates thatexhibit (i) an unmethylated status in normal brain (β ≤ 0.2,
SD < 0.1), (ii) a difference in DNA methylation (DM)
between averaged grade II and anaplastic cases higher
than DM > 30%, and (iii) are also methylated in the av-
eraged GBM group (β > 0.4, SD < 0.1), were selected for
validation. Furthermore, we investigated DNA hyper-
methylation events specific for precursor (PXA-4) and
anaplastic (PXA-5) PXA cases that retained normal
levels in the rest of the samples, including GBM, and
therefore represent specific DNA hypermethylation events
of this tumor entity.
Pyrosequencing and bisulfite genomic sequencing
In order to validate the results obtained from the DNA
methylation array, pyrosequencing was performed on se-
lected candidate genes as has been previously described,
on grade II PXA samples, anaplastic PXA samples (PXA
4-6), as well as in glioblastoma and normal brain samples.
Genomic DNA was converted using the EZ DNA
Methylation Gold kit (Zymo Research, Orange, CA,
USA). DNA methylation in clinical samples was studied
by pyrosequencing, which was performed on bisulphite-
treated DNA extracted from formalin-fixed paraffin-
embedded (FFPE) samples. Specific primers were designed
using the PyroMark Assay Design Software (QIAGEN-
version 2.0.01.15) for to examine the methylation status of
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regions (Additional file 1: Table S1). Pyrosequencing pri-
mer sequences were designed to hybridize with CpG-free
sites to ensure methylation-independent amplification.
PCR was performed with primers biotinylated to convert
the PCR product to single-stranded DNA templates. We
used the Vacuum Prep Tool (Biotage) to prepare single-
stranded PCR products according to the manufacturer’s
instructions. Pyrosequencing reactions and quantification
of DNA methylation were performed in a PyroMark Q96
System version 2.0.6 (QIAGEN) including appropriate
controls. For bisulfite genomic sequencing of MGMT
promoter sequence, specific sets of primers were designed
using the Methyl Primer Express software (Applied Biosys-
tems) (Fwd: GGTAAATTAAGGTATAGAGTTTTAGG;
Rev: ACCCAAACACTCACCAAAT), and a minimum of
eight clones were sequenced. It allows a positive display of
5- methyl cytosines in the gene promoter after bisulfite
modification as unmethylated cytosines appear as thy-
mines, while 5-methylcytosines appear as cytosines in the
final sequence.
Statistical analysis and Gene ontology analysis of
differentially methylated genes
In order to define DNA methylation patterns between
and inside groups of samples, statistical comparisons
were performed. Mann-Whitney U-test (False Discovery
Rate, FDR < 0.05) and Fisher’s exact test were performed
to compare differences between groups of glioblastoma
and normal brain sample sets, depending on the data
types of the variables being examined. DNA methylation
values of glioblastoma and normal brain samples were
averaged for comparative purposes. Furthermore, the
genes found differentially methylated on anaplastic PXA
cases exhibited a SD < 0.1 in the GBM cohort, and were
all detected as significantly hypermethylated in a large
series study [29]. Due to sample size, average values and
standard deviation of PXA were compared to the values
of DNA methylation patterns of glioblastoma and nor-
mal brain samples sets. Analyses were performed with
SPSS (version 11.5, SPSS Inc., Chicago, IL., USA). GO
enrichments for biological process ontology were calcu-
lated using the GOStats package under R statistical
software. Those terms below an adjusted (Benjamini-
Hochberg correction) p-value below 0.01 were selected
and considered significant.
Results
Clinical, histological and genetic characterization of
patient samples
In PXA patients, the male: female ratio was 1:0.8, in
GBM patients was 1:0.7, and in control cases 1:1.3. The
median age at diagnosis was in PXA patients 26 years
(Table 1), in GBM patients 60.6 years, and in controlcases 52.1 years. All PXA patients presented with a 4-8-
week history of epileptic seizures, dizziness and head-
ache, after that MRI diagnosis (Figure 1) was performed
and the tumors were diagnosed. All PXA patients under-
went complete surgical resection. The one patient diag-
nosed with a PXA with anaplastic features (PXA-5) was
the local relapse of one of the grade II PXA (PXA-4),
one year after complete tumor resection. Albeit being an
outlier for the median age at diagnosis, cases of PXA di-
agnosed in adults and elderly patients have been docu-
mented previously as well [31,32]. After resection of the
anaplastic PXA, adjuvant fractionated radiotherapy
(59Gy) and chemotherapy with temozolomide were per-
formed. All analyzed PXA show the typical characteristic
of this type of lesion (Table 1). Figure 1 shows comparative
immunohistochemical investigations with hematoxylin &
eosin (HE), glial fibrillary acidic protein (GFAP) and MIB-1
in the cases of grade II PXA and associated anaplastic
PXA, and illustrative examples of histological assess-
ment of BRAF V600E mutation (PXA-3) and CD34 im-
munoreactivity (PXA-1) are included on Additional file 2:
Figure S1. Patients with glioblastoma had undergone stand-
ard therapy with gross-total surgical resection followed
by adjuvant fractionated radiotherapy (median 59 Gy)
and chemotherapy with temozolomide (Stupp regime).
Detection of candidate-genes differentially methylated in
malignant PXA
Aiming to recognize changes attributable to malignant
transformation of PXA into GBM, we sought to identify
specific changes between grade II and anaplastic PXA
cases. To this end, we explored the DNA methylation
profiles in PXA patients, restricting the analysis to genes
being unmethylated (β < 0.2, SD < 0.1) in NB and meth-
ylated in GBM (β > 0.4, SD < 0.1) in any of the probes.
As a result, a pattern of progressive hypermethylation was
recognized, allowing the categorization of the analyzed
cases in three groups: (1) grade II PXA samples without
further recurrence; (2) anaplastic PXA cases and the cor-
responding grade II PXA precursor tumor; and (3) GBM
(Figure 2). PXA samples showed a progressive increase in
the frequency of hypermethylated CpGs correlating with
the presence of malignant features (>5 mitoses pro high-
power field and/or necrosis). A considerable number of
hypermethylated genes stand out the anaplastic PXA
cases and the one grade II PXA precursor tumor (PXA-4),
whereas no hypomethylation events were detected.
Interestingly, we found a series of genes showing DNA
hypermethylation (DM > 30%) at gene promoters re-
stricted to the malignant PXAs (Figure 2) as compared
with grade II samples. Specifically, this set of genes
(CD81, HCK, HOXA5, ASCL2, TES, AHR, DIO3, FZD9
and MOS) exhibited large DNA methylation increments
when comparing grade II PXAs and grade II PXA-4
Figure 1 Immunohistochemical characterization of grade II PXA and associated anaplastic PXA. Upper row: T1-weighted, gadolinium-
enhanced axial MRI showing the right parietal PXA at presentation (A), after surgical resection (B) and at the time of local relapse (C). Lower row:
Photomicrographs showing histological and immunohistochemical features of the grade II PXA and grade III PXA with anaplastic features
(HE, GFAP and MIB-1. The last one showed a higher positivity of 20% in the anaplastic PXA, whereas it was 10% in the grade II PXA).
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ently methylated in anaplastic PXA and in GBM pa-
tients as well (β > 0.4) but unmethylated (β < 0.2) in
normal brain, thus indicating an association between
increasing rate of hypermethylation events and the
presence of histological malignant features.Figure 2 DNA methylation alterations on grade II and malignant PXA
categorized on three groups: (1) grade II PXA (PXA 1-3); (2) precursor and a
increased DNA methylation when compared with grade II PXA. A set of ge
PXA, its grade II PXA precursor and GBM, whereas being unmethylated in a
shows methylated (red) and unmethylated (green) status of the probes.Pyrosequencing validation of the investigated genes
DNA methylation values obtained from the GoldenGate
methylation assay were validated by pyrosequencing in
those samples used for the discovery phase (PXA 4, 5),
as well as on an independent set of validation samples
(PXA 6-11). Specifically, we carried out validation of thesamples. Based on methylation frequencies, tumor samples can be
naplastic PXA (PXA 4-5) and (3) GBM. PXA-4 and PXA-5 samples show
nes was observed to be commonly hypermethylated in anaplastic
ll other grade II PXA and normal brain (squared in blue). Color scale
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anaplastic PXAs (including the one corresponding pre-
cursor grade II PXA), which were hypermethylated in
GBM cases as well. For technical limitations, from theFigure 3 Validation of DNA hypermethylation events in malignant tra
exhiited by the five selected markers on the GoldenGate DNA methylation
samples (b).nine genes identified, pyrosequencing could be per-
formed for five of them (CD81, TES, HOXA5, ASCL2,
HCK). The results obtained on the GoldenGate assay
(Figure 3A) were highly consistent with those obtainednsformation of PXA. Representation of DNA methylation levels
assay (a) and validated by pyrosequencing on an independent set of
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ples (Figure 3B). The five genes exhibited comparable
DNA hypermethylation gains in the anaplastic PXA
cases and were unmethylated in normal brain and grade
II PXA cases (Figure 3B). In addition, analysis of MGMT
promoter hypermethylation was also performed, and
comparable promoter DNA hypermethylation was found
in the anaplastic PXA samples as well as in the one
grade II tumor further relapsing as an anaplastic PXA
(Additional file 3: Figure S2).
Gene ontology (GO) analysis of genes differentially
methylated in malignant PXA
In order to gain insights into the impact of DNA hyper-
methylation on each of the established categories, we ex-
tracted the specific DNA methylation increases for each
sample set, taking the DNA methylation profile of normal
brain (NB) as a reference. By comparing normal brain and
malignant PXA cases, we identified 140 probes map-
ping to 116 unique genes gaining methylation (β > 30%;
NB < 20%) in the malignant PXA and precursor lesion
(Additional file 4: Table S2), and 49 probes (42 unique
genes) showed hypermethylation specifically in the ana-
plastic PXA cases. These genes retained an unmethy-
lated status in GBM and grade II PXA, indicating that
these DNA hypermethylation changes are inherent to
these tumor samples. As genes studied with the
methylation-specific BeadArray were selected for their
involvement in cancer, by definition they will be
enriched for functions deregulated in cancer. Even tak-
ing this limitation into consideration, gene ontology
analyses of the changes identified between malignantFigure 4 Gene ontology analysis of the genes hypermethylated in an
anaplastic grade III (PXA-5) PXA tumors with average methylation observed
system pathways, as well as other related with oncogenic potential such as
indicates number of genes involved on each biological process. Annotated
GO-terms resulting from the analysis (BH-adjusted p value < 0.01).PXA and normal brain, were observed to be preferen-
tially affecting genes involved in neuronal regulation,
including response to stimulus or protein phosphorilation;
in addition to pathways related with oncogenic progres-
sion, including cell motility and cell adhesion -cadherin
and integrin signaling pathways-, cell proliferation -Wnt
signaling components-, and angiogenesis among the af-
fected signaling circuits (Figure 4). These pathways were
considerably overlapping with those affected by DNA
hypermethylation in GBM patients, as has been previously
described [29]. When focusing on changes affecting grade
II PXA, only 23 probes mapping to 19 unique genes where
found differentially methylated in comparison with NB
(Additional file 5: Table S3) and no enrichment in bio-
logical functions resulted, confirming their benign nature.
Discussion
In the present study, we sought to explore the epigenetic
alterations associated to grade II PXA and those occur-
ring associated with the acquisition of histological malig-
nant features, such as mitoses (as above mentioned)
and/or necrosis. PXA WHO grade II is a slow-growing
astrocytic tumor, which is considered benign and pre-
sents a 10-years survival rate of 70% and a recurrence-
free lapse of 61% [8,33]. However, up to 20% PXA will
develop anaplastic features and may further progress to
secondary glioblastoma, exhibiting much more aggres-
sive phenotype and dropping significantly survival rates
with a median survival time of 15 months [8].
DNA methylation changes, and moreover those associ-
ated to malignant transformation of grade II PXA, had
not been investigated previously. In the present study,aplastic PXA. When comparing the precursor grade II (PXA-4) and
in normal brain, specific gains of methylation involve specific nervous
cell proliferation, motility and differentiation. Scale bar at the bottom
biological processes were selected among the statistically significant
Martínez et al. BMC Cancer 2014, 14:213 Page 9 of 11
http://www.biomedcentral.com/1471-2407/14/213we analyzed DNA hypermethylation on the promoter se-
quences of a panel of cancer-related genes in order to
investigate epigenetic alterations associated to this
process. To our knowledge, only MGMT methylation
status has been previously studied in PXA [28], while
the data on the epigenetic regulation of CD81, HCK,
TES, HOXA5 and ASCL2 in PXA patient have not been
documented before. Despite the low cohort size, we ob-
served comparable increases on the DNA methylation
levels in independent samples used for validation. Inter-
estingly, when analyzing differences in DNA methylation
affecting each sample type, we found a much higher
number of changes occurring in anaplastic PXA and the
grade II precursor tumor (116 genes) as compared with
fewer occurring in all other grade II PXA (19 genes) sam-
ples (Additional file 4: Table S2 and Additional file 5:
Table S3). Accumulation of genetic alterations has been
found associated to the pathogenesis and progression
of astrocytic tumours [34], and concomitantly, accumu-
lation of epigenetic lesions is present as well. Among the
changes identified, we observed a set of DNA hyperme-
thylation events in anaplastic PXA, its corresponding pre-
cursor grade II tumor, overlapping with DNA methylation
alterations also found in GBM (Figure 3). Several stud-
ies have previously reported frequent epigenetic disrup-
tion of CD81 in glioblastoma [29,35], supporting its
tumor-suppressor roles in this cancer type. Moreover,
promoter hypermethylation of the gene coding for Tes-
tin (TES) was also reported by us [29] and others
[36,37]. Its role acting as a negative regulator of cell
growth supports a role for tumor-suppression, as has
been proposed in diverse cancer types including ovarian
cancer [38] and acute lymphocytic leukemia [39]. DNA
hypermethylation of the transcription factor ASCL2 has
been identified in other cancers [40] and is involved in
the regulation of gene expression in the central and per-
ipheral nervous system [41]. Additionally, the pathways
deregulated by DNA methylation changes (Figure 4)
showed great consistency with those targeted in GBM,
and are concordant with previous observations reported
by us and others [29,37]. This data suggest that malignant
progression of grade II PXA towards anaplastic relapses
could be triggered by molecular mechanisms also involved
in GBM. This change of methylation status during malig-
nant progression could be also confirmed at the end-point
of anaplastic PXA cases (Additional file 4: Table S2). The
subset of genes validated in our study (CD81, TES,
HOXA5, ASCL2, and HCK) were not affected by DNA
hypermethylation in the grade II patients analyzed, and
therefore could be specifically associated to the progres-
sion of the disease in this patient (Figure 2 and 3). On the
other hand, we cannot rule out that the epigenetic alter-
ations observed could be attributable to individual-specific
DNA methylation phenomena; however, methylation ofthese genes has also been found in GBM in larger popula-
tion studies [29,35-37,42], thus indicating that they are
most probably involved in the pathogenesis and malignant
progression of astrocytic tumors.
Of note, considerable promoter hypermethylation was
found in MGMT promoter region, both in the precursor
and the anaplastic tumors (Additional file 3: Figure S2).
A recent report analyzing the methylation status of
MGMT in 11 grade II PXA concluded that this event
was infrequent in PXA [28]. Albeit this finding needs to
be assessed in larger population studies, the extensive
promoter hypermethylation we found in the anaplastic
PXA patient supported the indication of chemotherapy
with temozolomide in a similar pattern as it is in other
malignant tumors of astrocytic lineage [40].
The pathogenesis of PXA is largely unknown. Neverthe-
less, a series of molecular studies have described genomic
alterations in PXA patients [28,42-48] Chromosomal gains
and losses have been associated with PXA pathogenesis,
although prevalent losses -frequently involving chromo-
somes 7 and 9- were observed in grade II astrocytomas of
poor prognosis [28,42-44], accounting for a potential in-
activating mechanism of tumor suppressor genes. Further
genetic studies have also unveiled the high frequency of
BRAF V600E mutations in WHO grade II PXAs and
PXAs with anaplastic features (65 and 66% of cases, re-
spectively) [48], as well as homozygous deletion of
CDKN2A/p14(ARF)/CDKN2B in six out of ten tumors
analyzed in a different cohort [46]. DNA methylation al-
terations have been scarcely analyzed in PXA. Marucci
and colleagues examined MGMT promoter methylation
in 11 grade II PXA [28], but, to our knowledge, no add-
itional studies have been done to examine epigenetic alter-
ations in this setting. Methylation markers in a variety of
human cancers have proved trustworthy in clinical trials
for diagnostic and prognostic purposes. In other solid tu-
mors, DNA methylation markers have shown their rele-
vance in early diagnosis, prognosis of tumor progression,
or response to therapy and chemo-resistance [49,50]. For
instance, DNA methylation profiles were shown to correl-
ate with clinical parameters; specifically hypermethylation
of GATA6 transcription factor was found associated with
poor survival in GBM patients [35], or hypermethylation
of the pro-apoptotic CASP8 is a differential feature of
GBM relapses [51]. Though limited by the size of the pop-
ulations analyzed, our study suggests that DNA hyperme-
thylation mediated silencing of tumor suppressor genes in
PXA could be a relevant event contributing to malignant
progression, as also defined by other diffuse astrocytic tu-
mors. The diagnosis of grade II PXA at a high risk to recur
as a malignant tumor widens the therapeutic window for
intervention, in the form of early onset of adjuvant
chemotherapy, even at a grade II tumor stage. Thus, in
order to depict biomarkers with prognostic value on PXA
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further low-grade astrocytic tumors with risk to undergo
malignant transformation.
Conclusions
In the present study, though limited by sample con-
straints, we have identified promoter hypermethylation
of CD81, HCK, HOXA5, ASCL2 and TES genes in ana-
plastic cases compared to grade II PXA. These events
could potentially contribute to malignant progression of
PXA, since similar methylation increases were not ob-
served in grade II cases. Moreover, hypermethylation of
these genes were observed in GBM as well, suggesting
widespread epigenetic mechanisms of malignancy. This
study should be further confirmed in larger population
series aiming to identify clinically relevant biomarkers
for the management of the disease.
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